Skip to Content
Merck
All Photos(1)

Documents

M2300000

Minoxidil

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide, 6-(1-Piperidinyl)pyrimidine-2,4-diamine 3-oxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H15N5O
CAS Number:
38304-91-5
Molecular Weight:
209.25
MDL number:
MFCD00063409
UNSPSC Code:
41116107
PubChem Substance ID:
329817935
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

minoxidil

manufacturer/tradename

EDQM

mp

272-274 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

NC1=CC(=NC(=N)N1O)N2CCCCC2

InChI

1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2

InChI key

ZIMGGGWCDYVHOY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Minoxidil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Activates ATP-activated K+ channels; vasodilator; slow or stop hair loss and promote hair regrowth.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Esther J van Zuuren et al.
The Cochrane database of systematic reviews, 5(5), CD007628-CD007628 (2012-05-18)
Female pattern hair loss, or androgenic alopecia, is the most common type of hair loss affecting women. It is characterised by progressive shortening of the duration of the growth phase of the hair with successive hair cycles, and progressive follicular
E J van Zuuren et al.
The British journal of dermatology, 167(5), 995-1010 (2012-10-09)
Female pattern hair loss (FPHL) or androgenic alopecia is the most common type of hair loss affecting women with reduced hair density and can have a serious psychological impact. It is characterized by progressive replacement of slow cycling terminal hair
Marc R Avram et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 28(10), 894-900 (2002-11-02)
Over the last decade surgical management of hair loss has become an increasingly popular and satisfying procedure for both men and women, as innovations in donor harvesting, graft size, and hairline design have resulted in consistently natural-appearing hair restoration. In
Chester L Bowen et al.
Bioanalysis, 4(23), 2823-2832 (2012-12-12)
Stabilization of phase II metabolites is an important consideration during bioanalytical method development, method validation and sample analysis. Generic approaches to stabilize these metabolites during storage in liquid-based matrices include pH adjustment of samples prior to storage and/or temperature control;
Natasha Atanaskova Mesinkovska et al.
Dermatologic clinics, 31(1), 119-127 (2012-11-20)
Female pattern hair loss (FPHL) is the most common cause of alopecia in women. FPHL is characterized histologically with increased numbers of miniaturized, velluslike hair follicles. The goal of treatment of FPHL is to arrest hair loss progression and stimulate
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service